Skip to content

Three Quick Facts: Ilika, N4 Pharma and MediaZest

Three Quick Facts: Ilika, N4 Pharma and MediaZest

Here are three things you need to know in the financial markets this morning from investment writer, Tony Cross.

Slim pickings across the blue chip stocks for news this morning so we’ll take a quick look at exclusively what’s out from some of the smaller caps.

#1. Ilika completes construction of a clean room

AIM listed Ilika LON:IKA, the solid state battery specialists, have advised that they have completed the construction of a clean room and advanced various lines of technology acceptance, all of which are necessary for the production of its Stereax battery manufacturing. Testing will continue through calendar Q4, with product qualification in Q1 ‘22  and product sales expected in Q2 ’22.

#2. N4 Pharma provides an operations update

N4 Pharma LON:N4P, the company working to develop novel delivery systems for cancer treatments and vaccines, has provided an operations update. The work being undertaken to see how these delivery systems can combat COVID-19 are obviously of particular interest given the current climate, and although the note looks like a general round up, it could help lock in recent gains for the stock.

#3. MediaZest sees significant improvement in performance

There’s a trading update out from MediaZest LON:MDZ, a company which has over the last few months cropped up occasionally on our end of day wrap. As noted in the interim results published for the October-March period, new project work has led to a significant improvement in performance during the second half of the year and the outlook beyond 30th September and into FY 22 also looks encouraging. This is a thinly traded small cap stock and as such can respond dramatically to news updates.

Share this article

Invest with these platforms

Hargreaves Lansdown

IG

Interactive Brokers

Interactive Investor

Charles Stanley

IG

Interactive Brokers

Charles Stanley

Looking for great investing ideas? Get our free newsletter.

This article does not constitute investment advice.  Do your own research or consult a professional advisor.

Learn with our free 'How to' Guides

Our latest in-depth company reports

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

Aquis
CME Group
FP Markets
Pepperstone
Schroders

aberdeen
WisdomTree
ARK
Plus500
CMC Markets
Back To Top